Skip to main content
DAE HWA PHARM CO., LTD logo

DAE HWA PHARM CO., LTD — Investor Relations & Filings

Ticker · 067080 ISIN · KR7067080002 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-04-24 Director's Dealing
Country KR South Korea
Listing KO 067080

About DAE HWA PHARM CO., LTD

http://www.dhpharm.co.kr

DAE HWA PHARM CO., LTD. is a pharmaceutical company focused on the research, development, and manufacturing of finished drug products. The company's core competency lies in its advanced Drug Delivery System (DDS) technologies, particularly its proprietary lipid-based self-emulsifying platform, DHLASED. This technology enabled the development of Liporaxel®, the world's first approved oral formulation of the anticancer agent paclitaxel. The company's portfolio also includes analgesics and anti-inflammatory drugs, such as the LOXONA trans-dermal patch, as well as aesthetic products like hyaluronic acid fillers and consumer health solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean ‘임원ㆍ주요주주 특정증권등 소유상황보고서’, which is an insider ownership report disclosing an officer’s (Kim Woon Jang) holdings and trades. This matches the “Director’s Dealing” category (insider trades by directors/executives). It is not an announcement of a broader meeting or general regulatory notice, but the actual insider report. Therefore, the correct classification is DIRS.
2026-04-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a statutory disclosure detailing the shareholding status and changes in specific securities by an executive (“임원ㆍ주요주주 특정증권등 소유상황보고서”), including acquisition dates, stock counts before/after trades, and transaction details. This matches the insider/Director’s dealing category.
2026-04-21 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 0% confidence The document is titled “기업가치 제고 계획” (“Corporate Value Enhancement Plan”) and is a voluntary disclosure (자율공시) outlining the company’s dividend policy and longer-term plan to enhance shareholder value. It does not announce specific upcoming dividend amounts or payment dates, nor is it a full annual or quarterly report, financing transaction, or board change notice. It reads as a narrative plan rather than a formal financial statement or earnings release. There is no presentation deck structure, no audit opinion, and no takeover bid details. Therefore, it does not fit any of the more specific categories and defaults to a general regulatory filing.
2026-04-01 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal notification to the Financial Services Commission/Korea Exchange regarding the appointment, reappointment, and resignation of an outside director (‘사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고’). It details changes in the board composition, including names, dates, terms, and backgrounds of the outside director. This matches the definition of a Board/Management Information filing (announcement of changes in the company’s board of directors or senior management).
2026-04-01 Korean
타인에대한담보제공결정
Capital/Financing Update Classification · 1% confidence The document is a statutory disclosure under the Korean Capital Markets Act detailing a decision by the company’s board to grant collateral (a guarantee) on behalf of an affiliate (“타인에 대한 담보제공 결정”), including debtor/creditor identities, amounts, collateral details, resolution date, and related financials. It is not an earnings release, annual/interim report, board change notice, dividend, share issue, or other governance statement. This fits squarely as a financing arrangement update. Therefore, the correct classification is a Capital/Financing Update.
2026-03-31 Korean
[기재정정]타인에대한담보제공결정
Regulatory Filings Classification · 1% confidence The document is a statutory ‘‘정정신고(보고)’’ (correction report) under the Korean Capital Markets Act (자본시장법) detailing a third-party collateral provision decision. It’s not an earnings release, management change, dividend notice, etc., but a regulatory announcement of a material event (provision of collateral and related board resolution). This falls into the general ‘Regulatory Filings’ category (RNS) rather than a specific financial report or investor presentation.
2026-03-31 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.